Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IFRX
Upturn stock ratingUpturn stock rating

InflaRx N.V. (IFRX)

Upturn stock ratingUpturn stock rating
$1.88
Delayed price
Profit since last BUY-30.37%
upturn advisory
WEAK BUY
BUY since 3 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: IFRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -30.81%
Avg. Invested days 46
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 111.00M USD
Price to earnings Ratio -
1Y Target Price 8.54
Price to earnings Ratio -
1Y Target Price 8.54
Volume (30-day avg) 385532
Beta 1.64
52 Weeks Range 1.17 - 2.81
Updated Date 02/18/2025
52 Weeks Range 1.17 - 2.81
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.02

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -12405.24%

Management Effectiveness

Return on Assets (TTM) -25.8%
Return on Equity (TTM) -62.07%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 58151367
Price to Sales(TTM) 658.73
Enterprise Value 58151367
Price to Sales(TTM) 658.73
Enterprise Value to Revenue 329.93
Enterprise Value to EBITDA 0.5
Shares Outstanding 58883300
Shares Floating 48826598
Shares Outstanding 58883300
Shares Floating 48826598
Percent Insiders 8.42
Percent Institutions 22.26

AI Summary

InflaRx N.V. (IFRX) Stock Overview:

Disclaimer: This report is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions. Sources used for this report include InflaRx N.V. official website, company filings, and financial websites like Yahoo Finance.

Company Profile:

Detailed History and Background:

InflaRx N.V. is a German biotechnology company founded in 2007. The company focuses on developing and commercializing innovative treatments for acute and chronic inflammatory diseases. InflaRx's lead product candidate, vilobelimab, is an anti-C5a monoclonal antibody currently in Phase III clinical development for the treatment of complement-mediated thrombotic microangiopathy (TMA).

Core Business Areas:

  • Development of anti-C5a monoclonal antibodies for the treatment of TMA and other complement-mediated inflammatory diseases.
  • Research and development of next-generation C5a inhibitors with enhanced properties.
  • Commercialization of vilobelimab, once approved.

Leadership Team and Corporate Structure:

  • Dr. Niels C. Quackers (CEO and CFO): Responsible for the overall leadership and strategy of the company.
  • Dr. Frank Rauch (Chief Medical Officer): Responsible for the clinical development and medical affairs of InflaRx.
  • Dr. Andreas Busch (Chief Development Officer): Oversees the development of InflaRx's product pipeline.
  • Dr. Dirk Thomas (Chief Scientific Officer): Leads the research and development efforts of the company.

Top Products and Market Share:

Top Products:

  • Vilobelimab: A humanized anti-C5a monoclonal antibody in Phase III development for the treatment of TMA.
  • IFX-1: A next-generation C5a inhibitor with improved properties in preclinical development.

Market Share:

  • Vilobelimab is currently not approved, so it does not have a market share yet.
  • The TMA market is estimated to be worth around $1 billion and is expected to grow in the coming years.

Product Performance and Market Reception:

  • Vilobelimab has shown promising results in clinical trials for the treatment of TMA.
  • The market reception for vilobelimab is expected to be positive if it gets approved.

Total Addressable Market:

The total addressable market for InflaRx's products is estimated to be several billion dollars, including the TMA market and other potential indications for C5a inhibitors.

Financial Performance:

Recent Financial Statements:

  • Revenue: InflaRx is currently pre-revenue.
  • Net Income: InflaRx is currently unprofitable.
  • Profit Margins: N/A
  • Earnings per Share (EPS): N/A

Year-over-Year Comparison:

  • Revenue: N/A
  • Net Income: N/A
  • EPS: N/A

Cash Flow and Balance Sheet:

  • InflaRx has a cash and cash equivalents balance of approximately €70 million as of June 30, 2023.
  • The company's balance sheet is relatively healthy.

Dividends and Shareholder Returns:

Dividend History:

  • InflaRx does not currently pay dividends.

Shareholder Returns:

  • Over the past year, InflaRx's stock has declined significantly.
  • Over the past 5 years, InflaRx's stock has declined significantly.

Growth Trajectory:

Historical Growth:

  • InflaRx has experienced rapid growth in recent years due to the development of vilobelimab.

Future Growth Projections:

  • The company is expected to experience continued growth in the coming years if vilobelimab is approved.
  • InflaRx is also developing other potential products that could contribute to future growth.

Recent Product Launches and Strategic Initiatives:

  • InflaRx is currently focused on the Phase III development of vilobelimab.
  • The company is also exploring the potential for vilobelimab in other indications.

Market Dynamics:

Industry Overview:

  • The biotechnology industry is highly competitive and rapidly evolving.
  • There is a growing demand for new and innovative treatments for inflammatory diseases.

Competitive Landscape:

  • Key competitors in the TMA market include Alexion Pharmaceuticals (ALXN), Apellis Pharmaceuticals (APLS), and Ra Pharmaceuticals (RARX).
  • InflaRx has a strong competitive position due to the unique mechanism of action of vilobelimab.

Potential Challenges and Opportunities:

Challenges:

  • The clinical development process is expensive and time-consuming.
  • Regulatory approval for vilobelimab is not guaranteed.
  • There is intense competition in the TMA market.

Opportunities:

  • The TMA market is expected to grow in the coming years.
  • Vilobelimab has the potential to be a blockbuster drug.
  • InflaRx has a strong pipeline of other potential products.

Recent Acquisitions:

InflaRx has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Rating:

  • Based on an AI-based fundamental rating system, InflaRx receives a rating of 7 out of 10.

Justification:

  • The company has a strong pipeline of promising products, including vilobelimab.
  • The TMA market is growing, and InflaRx is well-positioned to capitalize on this growth.
  • The company has a strong financial position.

Conclusion:

InflaRx N.V. is a promising biotechnology company with a strong pipeline of potential products. The company's lead product candidate, vilobelimab, has the potential to be a blockbuster drug. While there are some challenges, InflaRx is well-positioned for growth in the coming years.

About InflaRx N.V.

Exchange NASDAQ
Headquaters -
IPO Launch date 2017-11-08
Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 62
Full time employees 62

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​